Here we critically review studies that used electroencephalography (EEG) or event-related
potential (ERP) indices as a biomarker of Alzheimer's disease. In the first part we overview …

Background The need for preventive therapies that interrupt the progression of Alzheimer's
disease (AD) before the onset of symptoms or when symptoms are emerging is urgent and …

Progressive cognitive decline in combination with a cerebrospinal fluid biomarker pattern of
low levels of amyloid-β1-42 and high levels of total tau and phosphorylated tau is typical of …

Notes 408 Biographies 408 Acknowledgments 409 References 409 The enormous
structural diversity of glycoconjugates mirrors their myriad biological functions in prokaryotic …

Alzheimer´ s disease (AD) and related forms of dementia are increasingly affecting the aging
population throughout the world, at an alarming rate. The World Alzheimer´ s Report …

Alzheimer's disease (AD) is a progressive and fatal neurodegenerative disease, with no
effective treatment or cure. A gold standard therapy would be treatment to slow or halt …

Frontotemporal dementia (FTD) covers a spectrum of neurodegenerative disorders with
different phenotypes, genetic backgrounds, and pathological states. Its clinicopathological …

Alzheimer's disease is a neurodegenerative disorder characterized by extracellular amyloid
plaque deposits, mainly composed of amyloid-beta peptide and intracellular neurofibrillary …

Background “Biological plausibility” is a concept frequently referred to in environmental and
public health when researchers are evaluating how confident they are in the results and …

Accumulation of the amyloid-beta (Aβ) peptide is a central factor in Alzheimer's disease (AD)
pathogenesis as supported by continuing evidence. This review concisely summarizes this …